Bisphosphonate-Related Osteonecrosis of the Jaws–An Initial Case Series Report of Treatment Combining Partial Bone Resection and Autologous Platelet-Rich Plasma

Curi, Marcos Martins; Cossolin, Giuliano Saraceni Issa; Koga, Daniel Henrique; Zardetto, Cristina Giovannetti Del Conte; Christianini, Silmara; Feher, Olavo; Cardoso, Camila Lopes; Santos, Marcelo Oliveira dos

doi:10.1016/j.joms.2011.02.078

Cited by 108 publications

(113 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This therapeutic choice did not interfere with the success of the surgery. Our results are similar to those obtained from Curi et al in another study [30,31]: there is no reason to interrupt bisphosphonate therapy when surgical treatment is indicated.…”

Section: Discussionsupporting

confidence: 92%

A Report on a 7-year Follow up of the Surgical Management with PRGF®- ENDORET® of Oncologic Patients Affected by Intravenous Bisphosphonate Related Osteonecrosis of the Jaw

Mozzati¹,

Gallesio²,

Pol³

et al. 2013

Surgery Curr Res

View full text Add to dashboard Cite

Mozzati et al., Surgery 2013, S12 http://dx.doi.org/10.4172/2161-1076.S12-011 Research ArticleOpen Access AbstractBRONJ is an important complication in bisphosphonate therapy that dramatically influences the patient's quality of life and requires immediate intervention. The situation is worsened by the fact that its management is still an open issue, with no definitive standard of care. The aim of this paper is to present the short, middle and long term (7 years) results of surgical treatment of 32 BRONJ cases involving the use of PRGFNo intraoperative complications were observed; the short period freedom from light complications was 84.4%, with complete remittal in a few weeks; after 7 years the freedom from complications and need of re intervention is 100%. The freedom from onset of a new BRONJ on untreated sites was 100% up to 4 years after which decreased to 82%. The surgical procedure with the applications of platelet-enriched preparations can thus be considered favorably tested, having led to rapid osseous remodeling and to a satisfactory closure of the mucosa thus shielding the area from infection and reducing symptomatology.

show abstract

Section: Discussionsupporting

confidence: 92%

A Report on a 7-year Follow up of the Surgical Management with PRGF®- ENDORET® of Oncologic Patients Affected by Intravenous Bisphosphonate Related Osteonecrosis of the Jaw

Mozzati¹,

Gallesio²,

Pol³

et al. 2013

Surgery Curr Res

View full text Add to dashboard Cite

show abstract

“…54 Comparisons between the outcomes of different therapies are also complicated by the inclusion of patients taking different BPs and doing so in an uncontrolled clinical manner. 71 The treatment outcome is considered a success when oral mucosal healing is maintained without bone exposure or infection and there is acceptable radiographic healing for a 12-month period after surgery. Therefore, following patients for at least 1 year postoperatively may be indicated to identify the possibility of recurrence of disease 71 ; this is in accordance with the results of our study, which showed a mean follow-up period of 12.9 AE 9.9 months.…”

Section: Ae 52mentioning

confidence: 99%

Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review

Fliefel

Tröltzsch

Kühnisch

et al. 2015

International Journal of Oral and Maxillofacial Surgery

299

213

View full text Add to dashboard Cite

“…This shows that if a case with Stage 3 or cases with well-defined sequestrum is left, operative treatment should be considered as a more cautious approach when non operative treatment fails. In addition to this basic principle in the treatment protocol, ozone therapy, surgical bone grafting, stimulation of bone with growth factor, tissue engineering applications and low dose laser therapy (LLLT) are applied for supportive treatment [7][8][9] (Figures 1& 2). There are many studies that show success of PRF in patients with MRONJ [10].…”

Section: Discussionmentioning

confidence: 99%

Leucocyte-Rich and Platelet-Rich Fibrin(L-PRF) for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Long Term Follow-up

Şahın¹

2018

BJSTR

View full text Add to dashboard Cite

Bisphosphonate-Related Osteonecrosis of the Jaws–An Initial Case Series Report of Treatment Combining Partial Bone Resection and Autologous Platelet-Rich Plasma

Cited by 108 publications

References 50 publications

A Report on a 7-year Follow up of the Surgical Management with PRGF®- ENDORET® of Oncologic Patients Affected by Intravenous Bisphosphonate Related Osteonecrosis of the Jaw

A Report on a 7-year Follow up of the Surgical Management with PRGF®- ENDORET® of Oncologic Patients Affected by Intravenous Bisphosphonate Related Osteonecrosis of the Jaw

Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review

Leucocyte-Rich and Platelet-Rich Fibrin(L-PRF) for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Long Term Follow-up

Contact Info

Product

Resources

About